Currently there is no approved medication for the treatment of non-alcoholic steatohepatitis (NASH). Volixibat is under development for the treatment of NASH based on its MOA and is supported by non-clinical and Phase 1 data. This is a Phase 2, 48-week, dose-finding study to examine the efficacy, tolerability, and safety of volixibat in adults with NASH.
March 2017 to April 2018
This project led by: Adnan Said, MD